Tamer I.  Khayal net worth and biography

Tamer Khayal Biography and Net Worth

Insider of TransMedics Group
Dr. Tamer I. Khayal M.D. serves as Chief Commercial Officer of the Company. He served as our Chief Medical Officer and Vice President of Clinical Development from 2006 to 2017 and as our Director of Clinical Development from 2001 to 2006. Prior to joining TransMedics, Dr. Khayal served for six years as Director of Clinical Affairs for Zentiva Group, a.s., a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s Middle East and Africa operations. Prior to his employment in the pharmaceutical industry, Dr. Khayal was a practicing physician.

What is Tamer I. Khayal's net worth?

The estimated net worth of Tamer I. Khayal is at least $1.86 million as of March 8th, 2024. Dr. Khayal owns 25,185 shares of TransMedics Group stock worth more than $1,862,179 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Khayal may own. Additionally, Dr. Khayal receives a salary of $748,780.00 as Insider at TransMedics Group. Learn More about Tamer I. Khayal's net worth.

How old is Tamer I. Khayal?

Dr. Khayal is currently 55 years old. There are 4 older executives and no younger executives at TransMedics Group. The oldest executive at TransMedics Group is Ms. Miriam C. Provost Ph.D., Vice President of Global Regulatory Affairs, who is 63 years old. Learn More on Tamer I. Khayal's age.

What is Tamer I. Khayal's salary?

As the Insider of TransMedics Group, Inc., Dr. Khayal earns $748,780.00 per year. The highest earning executive at TransMedics Group is Dr. Waleed H. Hassanein M.D., Founder, President, CEO & Director, who commands a salary of $1,460,000.00 per year. Learn More on Tamer I. Khayal's salary.

How do I contact Tamer I. Khayal?

The corporate mailing address for Dr. Khayal and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Tamer I. Khayal's contact information.

Has Tamer I. Khayal been buying or selling shares of TransMedics Group?

Tamer I. Khayal has not been actively trading shares of TransMedics Group during the last quarter. Learn More on Tamer I. Khayal's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), and Miriam Provost (VP). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, TransMedics Group insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $155,000.00. In the last year, insiders at the sold shares 27 times. They sold a total of 192,279 shares worth more than $15,267,229.83. The most recent insider tranaction occured on March, 8th when insider Tamer I Khayal sold 1,417 shares worth more than $124,412.60. Insiders at TransMedics Group own 6.7% of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 3/8/2024.

Tamer I. Khayal Insider Trading History at TransMedics Group

See Full Table

Tamer I. Khayal Buying and Selling Activity at TransMedics Group

This chart shows Tamer I. Khayal's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $73.94
Low: $73.89
High: $78.79

50 Day Range

MA: $83.45
Low: $70.86
High: $89.93

2 Week Range

Now: $73.94
Low: $36.42
High: $99.63

Volume

876,931 shs

Average Volume

700,890 shs

Market Capitalization

$2.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01